Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Erythromycin
Drug ID BADD_D00804
Description Erythromycin is a bacteriostatic antibiotic drug produced by a strain of Saccharopolyspora erythraea (formerly Streptomyces erythraeus) and belongs to the macrolide group of antibiotics which consists of [Azithromycin], [Clarithromycin], [Spiramycin] and others. It was originally discovered in 1952.[L5245] Erythromycin is widely used for treating a variety of infections, including those caused by gram-positive and gram-negative bacteria.[L5245,L7261] It is available for administration in various forms, including intravenous, topical, and eye drop preparations.[L5245]
Indications and Usage For use in the treatment of infections caused by susceptible strains of microorganisms in the following diseases: respiratory tract infections (upper and lower) of mild to moderate degree, pertussis (whooping cough), as adjunct to antitoxin in infections due to Corynebacterium diphtheriae, in the treatment of infections due to Corynebacterium minutissimum, intestinal amebiasis caused by Entamoeba histolytica, acute pelvic inflammatory disease caused by Neisseria gonorrhoeae, skin and soft tissue infections of mild to moderate severity caused by Streptococcus pyogenes and Staphylococcus aureus, primary syphilis caused by Treponema pallidum, infections caused by Chlamydia trachomatis, nongonococcal urethritis caused by Ureaplasma urealyticum, and Legionnaires' disease caused by Legionella pneumophila.
Marketing Status Prescription; Discontinued
ATC Code D10AF02; J01FA01; S01AA17
DrugBank ID DB00199
KEGG ID D00140
MeSH ID D004917
PubChem ID 12560
TTD Drug ID D02YIZ
NDC Product Code 45802-966; 76420-196; 13668-586; 68071-5279; 51927-1440; 52536-183; 12836-0304; 52536-180; 66267-975; 13985-605; 55718-161; 63739-053; 50090-0248; 43781-2103; 50090-1958; 24338-126; 55289-217; 24208-910; 50090-4616; 0093-5572; 0574-4024; 24338-102; 68071-4228; 17478-070; 0378-8075; 63187-267; 50090-5918; 24338-122; 52536-105; 69238-1485; 69238-1503; 45802-962; 0074-5614; 43063-569; 68308-250; 42571-384; 51552-0555; 69238-1471; 69238-1473; 63629-8653; 45802-038; 76003-0439; 73082-020; 24338-104; 46708-694; 75834-243; 68981-019; 70518-0465; 61919-090; 24338-124; 71209-101; 76420-212; 75834-242; 60432-671; 55154-7850; 71209-100; 0093-5571; 72189-036; 52565-027; 13668-588; 63629-8648; 68788-9328; 55289-075; 0378-8212; 66639-514; 73082-010; 38779-0842; 55289-025; 69238-1484; 52536-103; 53002-9050; 68071-2538; 63629-8652; 50090-0361; 82160-126; 64677-0005; 55289-525; 68788-9393; 24338-120; 64677-5100; 13668-606; 52334-001; 69238-1504; 51927-0082; 68071-4791; 59566-0125; 50090-1484; 13668-607; 50090-0339; 63187-608; 68071-4803; 52565-033; 69238-1472; 71205-265; 52536-186; 0404-7191
Synonyms Erythromycin | Erythromycin A | Erythromycin Phosphate | Phosphate, Erythromycin | Erythromycin Lactate | Lactate, Erythromycin | T-Stat | T Stat | TStat | Erymax | Erythromycin C | Erycette | Ilotycin
Chemical Information
Molecular Formula C37H67NO13
CAS Registry Number 114-07-8
SMILES CCC1C(C(C(C(=O)C(CC(C(C(C(C(C(=O)O1)C)OC2CC(C(C(O2)C)O)(C)OC)C)OC3C(C(CC(O3)C)N( C)C)O)(C)O)C)C)O)(C)O
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Gastrointestinal disordersAlanine aminotransferase 1P24298Not Available6648747; 6518350; 3510392; 7049029
Infusion site phlebitisIntercellular adhesion molecule 1P05362T2620314729754; 16297520; 11981426; 8835360
Injection site abscessIntercellular adhesion molecule 1P05362T2620314729754; 16297520; 11981426; 8835360
Injection site atrophyIntercellular adhesion molecule 1P05362T2620314729754; 16297520; 11981426; 8835360
Torsade de pointesPotassium voltage-gated channel subfamily H member 2Q12809T2025110219239; 10984545; 10868744
Torsade de pointesPotassium voltage-gated channel subfamily KQT member 1P51787T4952610219239; 10984545; 10868744
Torsade de pointesMisshapen-like kinase 1Q8N4C8Not Available10219239; 10984545; 10868744
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Abdominal discomfort07.01.06.001--Not Available
Abdominal pain07.01.05.0020.003274%
Anaphylactic shock24.06.02.004; 10.01.07.002--Not Available
Arrhythmia02.03.02.001--Not Available
Burning sensation17.02.06.001; 08.01.09.029--Not Available
Cerebral palsy18.04.04.004; 17.19.03.002; 03.10.03.0020.004365%Not Available
Chest pain22.02.08.003; 08.01.08.002; 02.02.02.011--Not Available
Colitis ulcerative10.02.01.004; 07.08.01.0050.002182%Not Available
Confusional state19.13.01.001; 17.02.03.005--
Deafness04.02.01.0010.007638%Not Available
Depression19.15.01.0010.002182%
Diarrhoea07.02.01.0010.004365%
Discomfort08.01.08.003--Not Available
Dizziness24.06.02.007; 17.02.05.003; 02.01.02.004--
Drug hypersensitivity10.01.01.0010.009821%Not Available
Dry skin23.03.03.001--
Dysgeusia17.02.07.003; 07.14.03.001--
Electrocardiogram QT prolonged13.14.05.004--
Erythema23.03.06.001--Not Available
Erythema multiforme23.03.01.003; 10.01.03.015--
Eye irritation06.04.05.003--Not Available
Eyelid oedema23.04.01.003; 10.01.05.001; 06.04.04.0040.003274%Not Available
Feeling abnormal08.01.09.014--Not Available
Gastrointestinal pain07.01.05.005--
Hallucination19.10.02.002--
Hepatic function abnormal09.01.02.001--Not Available
Hepatitis09.01.07.004--Not Available
Hepatotoxicity12.03.01.008; 09.01.07.009--Not Available
Hypersensitivity10.01.03.0030.003274%
Inflammatory bowel disease07.08.01.0160.002182%Not Available
The 1th Page    1 2 3    Next   Last    Total 3 Pages